Here are the S-1 registration statements from Biotricity Inc (BTCY) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow BTCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BTCY filings page.
Biotricity Inc. is registering up to 44,117,647 shares of common stock in a primary offering at an assumed price of $0.34 per share. The medical technology company provides remote cardiac monitoring solutions such as its FDA-cleared Bioflux and Biotres devices, a direct-to-consumer Bioheart monitor, and the Biocare disease management platform, aiming to build recurring technology-fee revenue from cardiac diagnostics and chronic care.
The company has expanded sales to 33 U.S. states and is investing in AI-driven analytics, supported in part by a $238,703 NIH grant, while partnering with major cloud providers for its cardiac AI model. However, Biotricity carries substantial financial risk, including approximately $21.1 million of indebtedness as of March 31, 2023, a cash balance of about $308,460, an accumulated deficit of $140.97 million, and a working capital deficiency of about $18.08 million as of September 30, 2025.
Auditors have expressed substantial doubt about its ability to continue as a going concern, and the company faces a Nasdaq delisting process after failing to meet the $35 million market value of listed securities requirement. The S-1 outlines numerous risks, including heavy leverage, the need for additional capital, potential dilution from preferred stock and convertible notes, reimbursement and regulatory uncertainties, intense competition in cardiac monitoring, and volatility and limited liquidity in its common stock.